

TABLE OF CONTENTS

Special Populations I	1
Special Populations I Panel	3

Cardiovascular Disease in Older Adults

By Snehal H. Bhatt, Pharm.D., FASHP, BCPS-AQ Cardiology, AACCP; and Joel Marrs, Pharm.D., MPH, FCCP, FAHA, FASHP, FNLA, BCACP, BCCP, BCPS-AQ Cardiology, ASH-CHC, CLS

Introduction	7
Antiplatelet Therapy in Older Adult Patients	16
Valvular Heart Disease in Older Adults	19
Atrial Fibrillation in Older Adults	20
Conclusion	23
Self-Assessment Questions	27

Mental Illness and Cardiovascular Disease

By Ian R. McGrane, Pharm.D., BCPS, BCCP; and Andrew J. Smith, Pharm.D., FCCP, BCPS, BCCP

Links Between Cardiovascular Disease and Mental Illness ..	31
Mental Illness Treatment and Its Impact on CVD	34
Role of the CV Pharmacist	41
Conclusion	48
Self-Assessment Questions	52

Special Populations II

Special Populations II Panel	59
------------------------------------	----

High-Cost Drugs and Cardiovascular Disease

By Dustin D. Spencer, Pharm.D., MBA, BCPS, BCCP; and Kathleen A. Packard, Pharm.D., FNAP, BCPS, AACCP

Introduction	63
High Drug Costs in the United States	64
Understanding the Pharmaceutical Supply Chain and How Prices are Determined	64
Payers and Prescription Drug Reimbursement	65
Strategies for Aligning Price and Value for Prescription Drugs	67
Impact of High-Cost Drugs on Patients with Cardiovascular Diseases	68
Cost-Effectiveness and Drug Value	70
Improving Patient Access to High-Cost Drugs	71
Clinical Pharmacy Strategies for Using High-Cost Drugs	74
Conclusion	77
Self-Assessment Questions	80

Cardiovascular Disease in Women

By Shannon W. Finks, Pharm.D., FCCP, BCPS, BCCP, AHSCP-CHC; and Kelly C. Rogers, Pharm.D., FCCP, FACC, BCCP

Introduction	85
Sex-Related Differences and Racial/Ethnic Disparities in CVD	85
CV Risk Factors in Women	86
Coronary Heart Disease Among Women	90
Management of CVD During Pregnancy	98

Role of the Pharmacist	106
Conclusion	107
Self-Assessment Questions	110

Special Populations III

Special Populations III Panel	117
-------------------------------------	-----

Medication Adherence and Cardiovascular Disease

By Michael Brenner, Pharm.D., BCPS, BCCP

Introduction	121
Nonadherence: Predictors and Barriers	122
Evidence Associated with Medication Nonadherence	125
Strategies and Interventions to Improve Medication Adherence	127
Role of the Pharmacist	132
Conclusion	133
Self-Assessment Questions	137

Drug Shortages and Medication Safety

By Erin R. Fox, Pharm.D., FASHP, BCPS; and Natasha Nicol, Pharm.D., FASHP

Introduction	141
Cause of Drug Shortages	142
Drugs Commonly on Shortage Lists	143
Alternative Drug Sources During Shortages	144
Government and Industry Response	146
Patient Safety and Drug Shortages	147
Drug Shortage Management Strategies	148
Resources	154
Conclusion	154
Self-Assessment Questions	157

Special Populations IV

Special Populations IV Panel	163
------------------------------------	-----

Chemotherapy-Associated Cardiomyopathy

By Jo E. Rodgers, Pharm.D., FCCP, FHFS, FAHA, BCPS, BCCP, CPP; and Amber B. Cipriani, Pharm.D., BCOP

Chemotherapy-Associated Cardiomyopathy	168
Hyperlinks to the activity	168
Self-Assessment Questions	170

Recorded Webcast: Precision Medicine in Cardiovascular Disease

By James C. Lee, Pharm.D., BCACP; and Yee Ming Lee, Pharm.D., BCPS

Recorded Webinar: Applying Precision Medicine in Cardiovascular Disease	174
Hyperlinks to the activity	174
Self-Assessment Questions	177